On October 28, Amicus Therapeutics issued a press release with an update on the progress of our Pompe
program as we received information from the US Food & Drug Administration (FDA) on the regulatory status of
our next-generation therapy for the treatment of late-onset Pompe disease. The entire Pompe community –
from individuals and families to patient advocacy organizations and their leaders – are our valued partners and
we want to share this information with you all within the context of the regulatory activities’ timeline.
Click here for more information